News - EGFR mutation - LARVOL VERI

Elevated Serum Direct Bilirubin and Smoking Status Are Prognostic Factors for EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy. (PubMed, Cancers (Basel))

Lung cancer is one of the leading causes of cancer-related death worldwide [...].

1 day ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer. (PubMed, Cancers (Basel))

The major translational relevance of this study is to exploit new targets for the development of innovative and improved therapeutic strategies with NOA drugs, over combinations including target genes within the oncogene pathway, to overcome resistance to TKI therapies in patients with NSCLC who are oncogene-addicted.

1 day ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • EGFR mutation • EGFR mutation + KRAS mutation

Tagrisso (osimertinib) • Koselugo (selumetinib) • gartisertib (M4344)

Remote organ cancer induces kidney injury, inflammation, and fibrosis and adversely alters renal function. (PubMed, Am J Physiol Renal Physiol)

Our results confirm cancer-kidney crosstalk in specific cancer types. In the era of precision medicine, further research is essential to identify at-risk oncology populations, enabling early detection and management of renal complications.

1 day ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • EGFR mutation • EGFR mutation + KRAS mutation

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome. (PubMed, Clin Respir J)

Combining cases from our oncology center and previous literature, we found that NSCLC patients with coexisting ALK fusion mutations and other mutations have poorer response to targeted therapy and poorer prognosis, and we also compared the efficacy rates of various types of coexisting mutations for different treatment regimens. Therefore, this review can help to evaluate the prognosis of NSCLC patients with coexisting mutations and the efficacy of targeted therapies and to find more favorable treatment options for patients with this type of coexisting mutations.

1 day ago

Review • Journal

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53)

TP53 mutation • EGFR mutation • ALK fusion • ALK mutation

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations. (PubMed, Front Pharmacol)

The patient, now on combination therapy for exceeding 12 months, exhibits further decreased tumor size and a high quality of life. This case underscores the importance of precise molecular diagnosis in guiding therapeutic strategies and provides a valuable reference for clinical decision-making in EGFR-positive NSCLC cases with atypical mutations.

2 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR positive

Gilotrif (afatinib) • Focus V (anlotinib)

A predictive nomogram for EGFR mutation status in lung adenocarcinoma manifesting as ground-glass nodules. (PubMed, J Thorac Dis)

The DCA showed that when it comes to EGFR mutation status prediction, the nomogram and the radiomics model showed better overall net benefit than the radiographic model. For preoperatively predicting the status of EGFR mutation in lung adenocarcinomas manifesting as GGNs, the CT-based radiomics analysis will be valuable.

2 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Prognostic impact of EGFR mutations in T1-4N0M0 lung adenocarcinoma: analyses focus on imaging and pathological features. (PubMed, J Thorac Dis)

EGFR mutations are associated with a favorable prognosis in nodules with lower IASLC grading or more ground glass opacity (GGO) components. The results were reversed in patients with higher IASLC grading or no GGO component.

2 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR positive

OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation. (PubMed, bioRxiv)

A mechanistic approach for partial inhibition of N-glycosylation delivers small molecules with anti-tumor activity in EGFR mutant NSCLC.

2 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study (PubMed, Magy Onkol)

Our results were similar to the previous period. The number of rebiopsies was essentially unchanged compared to the 2019-2021 period, which may be the main reason why we were able to identify the mutation in a lower percentage compared to the T790M hit rate described in the literature.

3 days ago

Journal

EGFR (Epidermal growth factor receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)

EGFR mutation • EGFR T790M

Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer. (PubMed, Clin Lung Cancer)

Oncogene mutations such as KRAS G12V and EGFR may have implications for cancer surveillance strategies and inform future treatment trials of stage I NSCLC.

4 days ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)

TP53 mutation • KRAS mutation • EGFR mutation • PTEN mutation • KRAS G13D • MET mutation • KRAS G12 • KRAS G13

Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study. (PubMed, Jpn J Clin Oncol)

Many patients require osimertinib dose reduction due to adverse events, but this process does not adversely affect the drug efficacy.

4 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR positive

Tagrisso (osimertinib)

Radiomics based on dual-layer spectral detector CT for predicting EGFR mutation status in non-small cell lung cancer. (PubMed, J Appl Clin Med Phys)

Nomogram integrating clinical factors and pretreatment DLCT radiomic features can help evaluate the EGFR mutation status of patients with NSCLC in a noninvasive way.

4 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Public assistance and survival equality in patients with EGFR mutation-positive lung cancer. (PubMed, Jpn J Clin Oncol)

Our findings suggest that neither the use of public assistance nor the urbanization level in the residential region significantly impacts the prognosis of Japanese patients with EGFR mutation-positive NSCLC.

4 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC. (PubMed, Cancer Sci)

We further discussed the factors determining the efficacy of ICIs in EGFR-mutated NSCLC patients, the mutation subtypes and microenvironment characteristics of potential responders. More importantly, we provided insights into areas worth further investigation in the future.

4 days ago

Review • Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)

EGFR mutation • EGFR wild-type

Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward. (PubMed, Bioorg Chem)

This review highlights the therapeutic approaches, and the challenges encountered in targeting EGFR-specific mutations. It suggests the need to develop more advanced higher-generation inhibitors for use in combinatorial therapy along with chemo-or-immune therapeutics in clinics as a breast cancer treatment strategy against relapse of the disease.

5 days ago

Review • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer. (PubMed, Transl Lung Cancer Res)

The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is widely used as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). In three cases of EGFR-L858R+V834L, other co-mutations, including TP53, CTNNB1, and RB1, were detected either before or after afatinib resistance. These results suggested that V834L cooperates with other coexisting mutations to influence the therapeutic efficacy of EGFR-TKIs.

6 days ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)

TP53 mutation • EGFR mutation • EGFR L858R • EGFR T790M • EGFR V834L

Tagrisso (osimertinib) • Gilotrif (afatinib)

Optimizing epidermal growth factor receptor-tyrosine kinase inhibitor treatment in lung cancer: a systematic review and meta-analysis of the influence of gastric acid suppressants. (PubMed, Transl Lung Cancer Res)

Careful consideration is advised when prescribing GASs, including adjusting administration timing, minimizing overlap duration, or opting for H2RAs over PPIs. Further research is needed to optimize treatment protocols, specifically addressing the duration of overlap time, to improve patient outcomes.

6 days ago

Retrospective data • Review • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Prognostic impact of targetable driver alterations in resected early-stage lung cancer. (PubMed, Transl Lung Cancer Res)

The lack of association between molecular alteration status and recurrence risk prevailed after multivariable adjustment for tumor stage and perioperative treatment (P=0.82 for KRAS G12C mutation and P=0.43 for any other molecular alteration). NSCLC patients with resected tumors that harbor molecular alterations have the same recurrence risk as patients with tumors without molecular alterations if treated with surgery plus chemotherapy when indicated.

6 days ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)

BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • ALK fusion • ALK mutation • KRAS G12

EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population. (PubMed, Transl Lung Cancer Res)

Further large-scale studies are needed to establish links between these mutations and clinical features at baseline and following treatment. Furthermore, moving forward, the development of novel drugs will be essential to fulfill the clinical unmet needs.

6 days ago

Review • Journal • EGFR exon 20

EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)

EGFR mutation • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation

Circulating tumor cells are associated with lung cancer subtypes: a large-scale retrospective study. (PubMed, Transl Lung Cancer Res)

We conducted a comprehensive analysis of the tumor properties, radiological features, and genomic characteristics that are significantly associated with CTCs in different lung cancer subtypes. This study helps elucidate the formation mechanism and relevant major regulation molecules of CTCs.

6 days ago

Retrospective data • Journal • Circulating tumor cells • Tumor cell

EGFR (Epidermal growth factor receptor) • CD68 (CD68 Molecule)

EGFR mutation

CELLSEARCH®

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) (clinicaltrials.gov)

P1, N=25, Completed, Dizal Pharmaceuticals | Recruiting --> Completed | Trial primary completion date: Aug 2024 --> May 2024

6 days ago

Trial completion • Trial primary completion date • Metastases

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)

EGFR mutation • HER-2 mutation

sunvozertinib (DZD9008)

Topological radiogenomics based on persistent lifetime images for identification of epidermal growth factor receptor mutation in patients with non-small cell lung tumors. (PubMed, Comput Biol Med)

The best radiogenomic approaches with the highest AUC were the random forest model trained with the Betti number (BN) map features (AUC = 0.984) in the internal test and the adapting boosting model trained with the BN map features (AUC = 0.717) in the external test. PLT features can be used as radiogenomic imaging biomarkers for the identification of EGFR mutation status in patients with NSCLC.

6 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung Cancer. (PubMed, JCO Precis Oncol)

We detected higher sensitivity to diagnose LMD using CSF CTC-based assay; 38% of LMD cases identified using this assay were missed by standard CSF cytology. CSF molecular testing using CSF cfDNA demonstrated high concordance with tissue-based molecular testing.

6 days ago

Journal • Circulating tumor cells • Tumor cell • Metastases

HER-2 (Human epidermal growth factor receptor 2)

EGFR mutation • HER-2 expression

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform. (PubMed, J Med Chem)

Compound 31 inhibited EGFR L858R/T790M/C797S in biochemical assays with a Ki = 2.1 nM and EGFR del19/T790M/C797S in a Ba/F3 cellular assay with an IC50 = 56.9 nM. The deuterated analogue of 31 (38) demonstrated dose-dependent tumor growth inhibition in a Ba/F3 EGFR del19/T790M/C797S CDX model by 47% at 50 mg/kg BID and 92% at 100 mg/kg BID.

6 days ago

Journal

EGFR (Epidermal growth factor receptor) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S

ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma: something new. (PubMed, Virchows Arch)

The authors review the sparse literature on molecular-genetic aberrations involving the epidermal growth factor receptor family of receptor tyrosine kinases (ERBB1/EGFR, ERBB2, ERBB3, and ERBB4) in uterine mesenchymal tumors, a review that suggests that such tumors may be pathologically heterogeneous. The potential clinical significance of demonstrating a targetable ERBB2/ERBB3 tyrosine kinase mutation or other EGFR family aberrations, as well as its distinctive pathologic profile, supports the segregation of the tumor reported herein as a distinct and emerging entity.

6 days ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NF1 (Neurofibromin 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • ATRX (ATRX Chromatin Remodeler) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • SOX10 (SRY-Box 10) • CD68 (CD68 Molecule) • MME (Membrane Metalloendopeptidase) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A) • NTRK (Neurotrophic receptor tyrosine kinase) • PDGFB (Platelet Derived Growth Factor Subunit B) • STAT6 (Signal transducer and activator of transcription 6) • MITF (Melanocyte Inducing Transcription Factor)

EGFR mutation • HER-2 mutation • CDKN2A deletion • ATRX mutation • ERBB3 mutation • NF1 deletion

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=72, Terminated, Navire Pharma Inc., a BridgeBio company | N=130 --> 72 | Trial completion date: Feb 2025 --> Jul 2024 | Active, not recruiting --> Terminated; Business decision

7 days ago

Enrollment change • Trial completion date • Trial termination • Metastases

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12

BMS-986466

Self-improving generative foundation model for synthetic medical image generation and clinical applications. (PubMed, Nat Med)

Using a large retrospective simulation analysis, we demonstrate MINIM's clinical potential by accurately identifying targeted therapy-sensitive EGFR mutations using lung cancer computed tomography images, which could potentially lead to improved 5-year survival rates. Although these results are promising, further validation and refinement in more diverse and prospective settings would greatly enhance the model's generalizability and robustness.

7 days ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • EGFR mutation

Pleiotropic tumor suppressive functions of PTEN missense mutations during gliomagenesis. (PubMed, iScience)

Moreover, expression of these PTEN mutations heightened EGFR activity by sequestering EGFR within endomembranes longer and affected its signaling behavior. Through comprehensive studies on global protein phosphorylation and kinase library analyses in cells with the G36E and L42R PTEN mutations, we identified distinct cancer-promoting pathways activated by EGFR, offering targets for treating GBM with these PTEN alterations.

8 days ago

Journal

EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog)

EGFR mutation • PTEN mutation • PTEN expression

Adjuvant osimertinib therapy guided by ctDNA-assessed MRD in resected EGFR-mutated stage IA-IIA non-small-cell lung cancer: a randomized clinical trial study protocol. (PubMed, Am J Cancer Res)

This study provides crucial insights into therapy guidance for EGFR-mutated NSCLC patients with MRD, potentially enhancing patient outcomes.

8 days ago

Clinical • Journal • Circulating tumor DNA

EGFR (Epidermal growth factor receptor)

EGFR mutation

Tagrisso (osimertinib)

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (clinicaltrials.gov)

P2, N=401, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2024 --> Sep 2025

8 days ago

Trial completion date • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression • EGFR mutation • ALK fusion

Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed

Better Brain: Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study (clinicaltrials.gov)

P2, N=70, Recruiting, Li-kun Chen

8 days ago

New P2 trial

EGFR (Epidermal growth factor receptor)

EGFR mutation

Avastin (bevacizumab) • Ivesa (firmonertinib)

Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer. (PubMed, Eur J Med Chem)

Furthermore, evaluations conducted in animal models have demonstrated that this drug effectively reduces tumor growth in vivo. In summary, (-)-9a boasts dual-targeting, potent antitumor activity, and immune-enhancing potential, presenting vast potential as a next-gen anticancer drug.

8 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • ALK mutation

Acquired multiple EGFR mutations‑mediated resistance to a third‑generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review. (PubMed, Oncol Lett)

Third-generation TKIs, such as osimertinib, almonertinib and furmonertinib, are effective for the treatment of NSCLC that is EGFR-sensitizing mutation-positive and T790M-positive. To the best of our knowledge, the present report describes the first case of a patient with lung adenocarcinoma who had multiple co-existing EGFR resistance mutations, including EGFR L718Q, EGFR C797S, EGFR C797G, EGFR L792H, EGFR V802F and EGFR V689L. These mutations conferred resistance to almonertinib, whilst maintaining sensitivity to afatinib.

9 days ago

Review • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR T790M • EGFR C797S • EGFR L718Q

Tagrisso (osimertinib) • Gilotrif (afatinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)

NEGOTIATE: NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations. (clinicaltrials.gov)

P2, N=0, Withdrawn, Sun Yat-sen University | N=37 --> 0 | Suspended --> Withdrawn

9 days ago

Enrollment change • Trial withdrawal • Surgery

EGFR (Epidermal growth factor receptor)

EGFR mutation

gefitinib

TtAgo-coupled-multiplex-digtal-RPA-CRISPR/Cas12a (TCMDC) for EGFR mutations detection. (PubMed, Talanta)

By combining RPA with CRISPR-Cas12a, we established a single-pot, ultra-sensitive (1 copy, 0.1 %), and visually detectable method for EGFR detection. We further verified the feasibility of this approach using clinical serum samples from lung cancer patients, achieving rapid (within 1 h) and visual detection of EGFR, thereby presenting a promising clinical tool for the detection of lung cancer.

9 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

Clinicopathological significance of sulfite oxidase expression in surgically resected lung adenocarcinoma. (PubMed, Med Mol Morphol)

High SUOX expression may be a new indicator of recurrence risk in surgically resected lung adenocarcinomas.

9 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR expression • EGFR positive

Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels. (PubMed, PeerJ)

The developed logistic regression model emerges as a promising tool for forecasting EGFR mutation status. It holds potential to aid clinicians in more precisely identifying patients likely to benefit from EGFR molecular testing and facilitating targeted therapy decision-making, particularly in scenarios where molecular testing is impractical or inaccessible.

9 days ago

Retrospective data • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways. (PubMed, Front Oncol)

Therefore, we suggest that there is an underappreciated association between the HER2-low subtype and endocrine resistance. In this perspective piece, we explore the evidence linking the HER2-low subtype with the various pathways to endocrine resistance and suggest that there are signaling networks in HER2-low tumors that intersect endocrine resistance and can be effectively targeted.

9 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

ER positive • EGFR mutation • HER-2 negative • HER-2 negative + ER positive

10d

ARC-4: A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (clinicaltrials.gov)

P1, N=77, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed

10 days ago

Trial completion

EGFR (Epidermal growth factor receptor)

EGFR mutation

Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)

10d

Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. (PubMed, Chin Med J (Engl))

For unresectable stage III EGFR mutant NSCLC, RT and TKI are both essential. Based on the current evidence, RT-TKI brings the best survival advantage, while CRT-TKI needs further estimation. Large randomized clinical trials are urgently needed to explore the appropriate application sequences of TKI, radiotherapy, and chemotherapy.

10 days ago

Clinical • Journal • PD(L)-1 Biomarker

EGFR (Epidermal growth factor receptor)

EGFR mutation

Imfinzi (durvalumab)

10d

CT and MRI bimodal radiomics for predicting EGFR status in NSCLC patients with brain metastases: A multicenter study. (PubMed, Eur J Radiol)

Our CT and MRI bimodal radiomics nomogram could timely and accurately evaluate the likelihood of EGFR mutation in patients with limited access to necessary materials, thus making up for the shortcoming of plasma sequencing and promoting the advancement of precision medicine.

10 days ago

Clinical • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation

12d

Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy. (PubMed, Br J Cancer)

Afatinib is a viable treatment option for tissue or ctDNA-detected EGFR mutant NSCLC comorbid patients, with a proportion achieving long-term clinical benefit. Plasma ctDNA testing improved EGFR mutant identification and its clearance predicted improved PFS and OS.

12 days ago

Journal • Circulating tumor DNA

EGFR (Epidermal growth factor receptor)

EGFR mutation

Gilotrif (afatinib)